Endoluten vs Humanin

Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

Endoluten is a Khavinson-class peptide bioregulator derived from pineal gland tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore physiological circadian regulation and melatonin synthesis by modulating gene expression in aging pineal epithelial cells through interaction with chromatin regulatory elements. As a pineal tissue-derived bioregulator, Endoluten operates within the mechanistic framework established for the Khavinson class: short peptides (2–4 amino acids) are proposed to bind specific DNA regulatory sequences in tissue-target cells, activating gene expression programs that decline with age and restoring physiological function through epigenetic mechanisms rather than receptor agonism. Published research on Khavinson-class peptide bioregulators as a class has characterized this peptide-DNA interaction mechanism and documented restorative effects on tissue-specific physiological parameters in aging animal models and human observational studies, providing class-level biological plausibility for pineal peptide bioregulators as age-related circadian and neuroendocrine regulators. Endoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed published studies using the Endoluten name specifically characterize its clinical outcomes in controlled trials, and its use is confined to the Russian integrative and anti-aging medicine context where Khavinson bioregulators are commercially available.

Mitochondria-derived peptide; binds gp130 receptor, activates STAT3/JAK pathway; inhibits BAX-mediated apoptosis; improves insulin sensitivity

Humanin is a mitochondrially encoded 21-amino-acid peptide originally identified through its capacity to suppress neuronal apoptosis induced by familial Alzheimer's disease gene products, now recognized as a founding member of the class of mitochondrial-derived peptides (MDPs) with broad cytoprotective actions in neurons, cardiomyocytes, and other metabolically stressed cell types. Humanin exerts its cytoprotective effects through multiple mechanisms: extracellularly, it binds insulin-like growth factor-binding protein 3 (IGFBP-3) to regulate IGFBP-3's interaction with nuclear import machinery and modulate its proapoptotic signaling; intracellularly, it inhibits c-Jun NH2-terminal kinase (JNK) activation through SH3-binding protein 5 to suppress stress-induced apoptotic cascades. PNAS research established that humanin interacts with IGFBP-3 to regulate cell survival and apoptosis, characterizing a molecular basis for its anti-apoptotic activity, and subsequent work identified JNK inhibition as an additional neuroprotective mechanism in humanin-treated neuronal preparations. Humanin is a research compound with no regulatory approval in any jurisdiction; published evidence is predominantly from in vitro and preclinical models, and no human clinical trials have been completed to establish pharmacokinetic, safety, or efficacy parameters for exogenous humanin administration.